Patents by Inventor Leonard G. Presta

Leonard G. Presta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210371842
    Abstract: The present disclosure relates to antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. In one embodiment, the derivatives described herein lack or have reduced intrinsic coagulant activity.
    Type: Application
    Filed: June 18, 2019
    Publication date: December 2, 2021
    Inventors: Pamela B. Conley, Genmin Lu, Leonard G. Presta, John T. Curnutte
  • Publication number: 20210355239
    Abstract: Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and/or CL domains, in the VH and/or VL domains, or a combination thereof.
    Type: Application
    Filed: April 27, 2021
    Publication date: November 18, 2021
    Inventors: Dunja UROSEV, Stacey A.L. TOM-YEW, Leonard G. PRESTA, Mario SANCHES
  • Patent number: 11161915
    Abstract: Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and/or CL domains, in the VH and/or VL domains, or a combination thereof.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: November 2, 2021
    Assignee: ZYMEWORKS INC.
    Inventors: Dunja Urosev, Stacey A. L. Tom-Yew, Leonard G. Presta, Mario Sanches
  • Patent number: 11147886
    Abstract: Bispecific antigen-binding constructs e.g., antibodies conjugated to drugs (ADCs), which bind CD3 and other cell-surface target antigen such as tumor antigens e.g., CD19, CDH3, HER2, HER3 and EGFR antigens and methods of use are disclosed.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: October 19, 2021
    Assignee: Zymeworks Inc.
    Inventors: Gordon Yiu Kon Ng, Leonard G. Presta, Thomas Spreter Von Kreudenstein
  • Publication number: 20210317208
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: August 30, 2019
    Publication date: October 14, 2021
    Applicant: Alector LLC
    Inventors: Patricia CULP, Helen LAM, Wei-Hsien HO, Leonard G. PRESTA, Arnon ROSENTHAL
  • Publication number: 20210317211
    Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, using an anti-TREM2 antibody or antigen binding fragment thereof.
    Type: Application
    Filed: June 10, 2021
    Publication date: October 14, 2021
    Inventors: Michel Streuli, Leonard G. Presta, Venkataraman Sriram, Aritra Pal, Nadine Jahchan, Mikhail Binnewies, Joshua L. Pollack, Xiaoyan Du
  • Publication number: 20210277129
    Abstract: Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: February 9, 2021
    Publication date: September 9, 2021
    Inventors: Lara Lewis MCGRATH, Fabien DÉPIS, Changyun HU, Leonard G. PRESTA, Joshua Adam BUGGÉ
  • Patent number: 11072662
    Abstract: Provided herein are humanized antibodies specific for CLL-1.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: July 27, 2021
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Ying-Ping Jiang, Jagath R. Junutula, Leonard G. Presta, Naoya Tsurushita
  • Patent number: 11028182
    Abstract: Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2. The antigen-binding constructs comprise at least one antigen-binding polypeptide construct that binds to ECD2 of HER2 (HER2 ECD2) with increased affinity compared to a wild-type 2C4 antibody. Such antigen-binding polypeptide constructs comprise one or more amino acid modifications in the framework region and/or CDRs compared to the amino acid sequence of a wild-type 2C4 antibody that increase affinity of the antigen-binding polypeptide construct for ECD2 by 2-fold or greater. The antigen-binding constructs can inhibit the growth of HER2-expressing breast cancer cells and gastric cancer cells. Antigen-binding constructs in biparatopic format are internalized in HER2-expressing cells.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 8, 2021
    Assignee: Zymeworks Inc.
    Inventors: Eric Escobar-Cabrera, Leonard G. Presta
  • Publication number: 20210101983
    Abstract: Provided herein are anti-TREM1 antibodies and related methods of making and using anti-TREM1 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM1 antibody or antigen binding fragment thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 8, 2021
    Inventors: Christopher Chan, Aritra Pal, Venkataraman Sriram, Leonard G. Presta, Tiep Tu Le, Linda Liang
  • Publication number: 20200385473
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 10, 2020
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sung Young KIM, Leonard G PRESTA, Jan-Willem THEUNISSEN
  • Publication number: 20200369739
    Abstract: This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-? receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.
    Type: Application
    Filed: June 5, 2018
    Publication date: November 26, 2020
    Applicant: Relinia, Inc.
    Inventors: David C Foster, Lutz B Giebel, Leonard G Presta
  • Patent number: 10836828
    Abstract: Provided herein are anti-TREM1 antibodies and related methods of making and using anti-TREM1 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM1 antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: November 17, 2020
    Assignee: PIONYR IMMUNOTHERAPEUTICS, INC.
    Inventors: Christopher Chan, Aritra Pal, Venkataraman Sriram, Leonard G. Presta, Tiep Tu Le, Linda Liang
  • Patent number: 10766959
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: September 8, 2020
    Assignee: Pierre Fabre Medicament
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • Publication number: 20200270360
    Abstract: Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.
    Type: Application
    Filed: August 28, 2018
    Publication date: August 27, 2020
    Inventors: Paul A. Jaminet, Shou-Ching S. Jaminet, Harold F. Dvorak, Leonard G. Presta
  • Publication number: 20200255546
    Abstract: The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.
    Type: Application
    Filed: January 16, 2020
    Publication date: August 13, 2020
    Inventors: Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
  • Publication number: 20200255529
    Abstract: Provided herein are anti-TREM1 antibodies and related methods of making and using anti-TREM1 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM1 antibody or antigen binding fragment thereof.
    Type: Application
    Filed: April 17, 2020
    Publication date: August 13, 2020
    Inventors: Christopher CHAN, Aritra PAL, Venkataraman SRIRAM, Leonard G. PRESTA, Tiep Tu LE, Linda LIANG
  • Publication number: 20200140546
    Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.
    Type: Application
    Filed: October 14, 2019
    Publication date: May 7, 2020
    Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
  • Patent number: 10618978
    Abstract: The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an AD-ME-modulating moiety, and their uses.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 14, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
  • Patent number: 10556959
    Abstract: The present disclosure relates generally to anti-CD39 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: February 11, 2020
    Assignee: Xencor, Inc.
    Inventors: Guoqing Chen, Gregory M. Hayes, Jan-Willem Theunissen, Edward Thein H. Van Der Horst, Leonard G. Presta